Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 8
Treatment-assignment count: 0
Stratification count: 1
Cdx Established Context
PD-L1 expression
melanoma · Immune Checkpoint Inhibitor
PD-L1 expression is flagged as cdx established context because public trials show inclusion required evidence in 15 contexts. FDA CDx context exists.
Threshold snippets
Fragmentation view
Threshold count: 5
Common snippets: BRAF V600E | MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 1
Recent signals: 1
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT02978625 | https://clinicaltrials.gov/study/NCT02304458 | https://clinicaltrials.gov/study/NCT03684785 | https://clinicaltrials.gov/study/NCT01844505 | https://clinicaltrials.gov/study/NCT03126461 | https://clinicaltrials.gov/study/NCT02736123 | https://clinicaltrials.gov/study/NCT02775851 | https://clinicaltrials.gov/study/NCT03063450 | https://clinicaltrials.gov/study/NCT03033576 | https://clinicaltrials.gov/study/NCT02625337 | https://clinicaltrials.gov/study/NCT03374839 | https://clinicaltrials.gov/study/NCT05704933 | https://clinicaltrials.gov/study/NCT04207086 | https://clinicaltrials.gov/study/NCT02332668 | https://clinicaltrials.gov/study/NCT06034860